Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 37, 2002 - Issue 3
Submit an article Journal homepage
13
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Effect of Interferon-α Induction Therapy on Genotype 2b/3a and Low Viral Load Hepatitis C Virus Infection: A Randomized Multicentre Study

K. Bjøro
,
H. Bell
,
B. Myrvang
,
K. Skaug
,
N. Raknerud
,
P. Sandvei
,
S. Størseth
,
S. Ritland
,
S. Lund-Tønnesen
,
A. Bucher
&
K. B. Hellum
 show all
Pages 344-349 | Published online: 08 Jul 2009

  • Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;32:1501-6.
  • Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. Meta-Analysis. J Hepatol 1991;13:192-9.
  • Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
  • Bjøro K, Krarup H, Bell H, Christophersen P, Evensen S, FrolandSS, et al. Two dose regimens of recombinant interferon-alpha-2b in chronic hepatitis C virus infection. Biochemistry, hepatitis C virus RNA, and liver histology as response indices. Scand J Gastroenterol 1995;30:1119-24.
  • Bell H, Hellum K, Harthug S, Maeland A, Ritland S, Myrvang B, et al. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group. Scand J Infect Dis 1997;29:17-22.
  • Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH, Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Int Med 1996;125:634-9.
  • Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH, Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Int Med 2000;132:296-305.
  • Idilman R, De Maria N, Colantoni A, Dokmeci A, Van Thiel DH. Interferon treatment of cirrhotic patients with chronic hepatitis C. J Viral Hepatit 1997;4:81-91.
  • Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks. Hepatology,1994;19:280-5.
  • Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996;24:778-89.
  • Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus interferon alfa. Hepatology 1997;26:226-31.
  • Ouzan D, Babany G, Valla D, Opolon P. Comparison of high initial and fixed-dose regimens of inerferon-alpha2a in chronic hepatitis C: a randomized controlled trial. French Multicenter Interferon Study Group. J Viral Hepatitis 1998;5:53-9.
  • Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-7.
  • Reddy RK, Layden T, Hollinger B. Interferon alfacon-1 induction therapy: a multicenter trial in subject with chronic hepatitis C virus infection. Hepatology 2000;32 Suppl 4:837A.
  • Sjogren MH, Holtzmuller C, Sjogren. Failure of interferon induction dosing to alter sustained response rates in patients with chronic hepatitis C. Gastroenterology 2000;118 Suppl 4:6739A.
  • McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy. N Engl J Med 1998;339:1485-92.
  • Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998;352:1426-32.
  • Bjøro K, Bell H, Hellum KB, Skaug K, Raknerud N, Sandvei P, et al. The effect of combined interferon-a induction therapy and ribavirin on chronic hepatitis C virus infection -- a randomised multicenter study. Scand J Gastroenterol. In press.
  • Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-11.
  • Garson JA, Ring CJA, Tuke PW. Improvement of HCV genom detection with 'short' PCR products. Lancet 1991;338:1466-7.
  • Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1982;5:431-8.
  • Lee WM, Reddy KR, Tong MJ, Black M, van Leeuwen DJ, Hollinger F, et al. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group. Hepatology 1998;28:1411-5.
  • Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
  • Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J, Is an 'A la carte' combination interferon alfa-2b plus ribavirin regimen posible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000;31:211-8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.